These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34154994)

  • 21. Human Pharmacokinetic and CYP3A Drug-Drug Interaction Prediction of GDC-2394 Using Physiologically Based Pharmacokinetic Modeling and Biomarker Assessment.
    Yu J; Tang F; Ma F; Wong S; Wang J; Ly J; Chen L; Mao J
    Drug Metab Dispos; 2024 Jul; 52(8):765-774. PubMed ID: 38811156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
    Ou Y; Xu Y; Gore L; Harvey RD; Mita A; Papadopoulos KP; Wang Z; Cutler RE; Pinchasik DE; Tsimberidou AM
    Br J Clin Pharmacol; 2019 Mar; 85(3):530-539. PubMed ID: 30428505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors.
    Chen G; Sun K; Michon I; Barter Z; Neuhoff S; Ghosh L; Ilic K; Song IH
    J Clin Pharmacol; 2024 May; 64(5):590-600. PubMed ID: 38009271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults.
    Townsend R; Dietz A; Hale C; Akhtar S; Kowalski D; Lademacher C; Lasseter K; Pearlman H; Rammelsberg D; Schmitt-Hoffmann A; Yamazaki T; Desai A
    Clin Pharmacol Drug Dev; 2017 Jan; 6(1):44-53. PubMed ID: 27273461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
    Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
    Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
    Li J; Kankam M; Trone D; Gammon G
    Br J Clin Pharmacol; 2019 Sep; 85(9):2108-2117. PubMed ID: 31173645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting the Drug-Drug Interaction Mediated by CYP3A4 Inhibition: Method Development and Performance Evaluation.
    Ren HC; Sai Y; Chen T; Zhang C; Tang L; Yang CG
    AAPS J; 2021 Dec; 24(1):12. PubMed ID: 34893925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.
    Frechen S; Junge L; Saari TI; Suleiman AA; Rokitta D; Neuvonen PJ; Olkkola KT; Fuhr U
    Clin Pharmacokinet; 2013 Sep; 52(9):763-81. PubMed ID: 23653047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions.
    Prieto Garcia L; Janzén D; Kanebratt KP; Ericsson H; Lennernäs H; Lundahl A
    Drug Metab Dispos; 2018 Oct; 46(10):1420-1433. PubMed ID: 30068519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.
    Yamazaki S; Loi CM; Kimoto E; Costales C; Varma MV
    Drug Metab Dispos; 2018 Aug; 46(8):1200-1211. PubMed ID: 29739809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method.
    Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
    AAPS J; 2020 Oct; 22(6):129. PubMed ID: 33033962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.
    Mulford DJ; Ramsden D; Zhang L; Michon I; Leifke E; Smith N; Jones HM; Scarpignato C
    CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):532-544. PubMed ID: 36896795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An open-label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people.
    Chen J; Li J; Wu J; Song Y; Li L; Zhang J; Dong R
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1252. PubMed ID: 39073244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
    Yu Y; Loi CM; Hoffman J; Wang D
    J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the Potential for Drug-Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data.
    Bergagnini-Kolev M; Kane K; Templeton IE; Curran AK
    AAPS J; 2023 Jun; 25(4):62. PubMed ID: 37344751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
    Narayanan R; Hoffmann M; Kumar G; Surapaneni S
    Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.
    Quinney SK; Zhang X; Lucksiri A; Gorski JC; Li L; Hall SD
    Drug Metab Dispos; 2010 Feb; 38(2):241-8. PubMed ID: 19884323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.
    Li A; Yeo K; Welty D; Rong H
    Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
    Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
    J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.